New laboratory for University of Basel’s Department of Biomedicine | Latest project in research and health sector | Contract worth over CHF 250 million | BIM and Lean Construction used for planning and execution
Ad hoc announcement pursuant to Art. 53 LR
Glattpark (Opfikon), 18 October 2022 – The University of Basel has contracted Implenia Division Buildings to build a new laboratory complex for its Department of Biomedicine.
The Department of Biomedicine (DBM) at the University of Basel is bringing all the experimental laboratory research done by the medical faculty together in this latest new-build. Located on the life sciences campus at the Schällemätteli site in Basel, the new building will house an optimal combination of research, teaching and applied medicine in a single location.
Implenia, in the role of total contractor, won the contract thanks to its impressive team of experts as well as to its many years of experience and proven competence across similar laboratory and healthcare building projects. Furthermore, as the leading Swiss construction and real estate service provider, Implenia can supply the essential civil engineering, construction and other skills from a single source.The contract is worth over CHF 250 million and includes execution planning, construction and commissioning of the building. The project starts this month with an optimisation phase and is expected to last until mid-2028. The complex should open for operations in 2031. A floor area of approx. 37,000 m2 spread over three basements, a ground floor and eight upper floors, provides space for laboratories, offices and seminar rooms. Planning for the building is based on the Minergie standard. In addition to high technical and hygiene standards, the building’s flexibility is also very important for research. Building Information Modeling (BIM) methods are being used for the planning and construction of the new laboratory complex. These include integrated planning using models from all the specialist disciplines, model coordination and testing with digital tools, and integration of user requirements using Roombook and virtual reality (VR).Digital Lean Construction (e.g. LCM Digital) is being used to schedule service packages, show dependencies, reduce the complexity of work steps and carry out quality and deadline control.
André Wyss, CEO of Implenia, is delighted with the new order: “This large and complex laboratory construction project is right in line with Implenia’s strategy. We would like to thank the University of Basel for its trust and look forward to building the new laboratory complex together. In recent years, Division Buildings has completed several interesting projects involving the planning and construction of buildings for research, education and healthcare. Our capabilities have evolved accordingly. These growth areas within the Swiss real estate sector are, and will remain, very important to Implenia’s work.”
Dates for investors: 1 November 2022: Capital Markets Day
1 March 2023: Annual results 2022, Analysts and Media Conference
28 March 2023: Annual General Meeting
As Switzerland’s leading construction and real estate service provider, Implenia develops and builds homes, workplaces and infrastructure for future generations in Switzerland and Germany. It also offers tunnelling and related infrastructure projects in further markets. Formed in 2006, the company can look back on around 150 years of construction tradition. The company brings together the know-how of its highly skilled development, planning and execution units under the umbrella of an integrated leading multinational construction and real estate service provider. With its broad offering and the expertise of its specialists, the Group realises large, complex projects and provides client-centric support across the entire life cycle of a building or structure. It focuses on client needs and on striking a sustainable balance between commercial success and social and environmental responsibility. Implenia, with its headquarters in Opfikon near Zurich, employs more than 7,700 people across Europe and posted revenue of CHF 3.8 billion in 2021. The company is listed on the SIX Swiss Exchange (IMPN, CH0023868554). More information can be found at implenia.com.